Plus Therapeutics (PSTV) Accounts Payables (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Accounts Payables data on file, last reported at $6.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $6.2 million, down 33.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (down 33.24% YoY), and the FY2025 annual result was $5.9 million, down 47.55% from the prior year.
• Accounts Payables climbed to $6.2 million in Q1 2026 per PSTV's latest filing, from $5.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $11.6 million in Q3 2025 and troughed at $3.2 million in Q1 2022.
• A 5-year average of $7.1 million and a median of $6.5 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 226.85% in 2022, then plunged 47.55% in 2025.
• A 5-year view of Accounts Payables shows it stood at $8.4 million in 2022, then dropped by 20.72% to $6.6 million in 2023, then jumped by 70.23% to $11.3 million in 2024, then sank by 47.55% to $5.9 million in 2025, then gained by 4.0% to $6.2 million in 2026.
• Business Quant data shows PSTV's Accounts Payables at $6.2 million in Q1 2026, $5.9 million in Q4 2025, and $11.6 million in Q3 2025.